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ABSTRACT
Altering the Regiospecificity of C6 Indole Prenyltransferases Towards Drug Development
by Ahmed R Aoun

Prenyltransferase (PT) biocatalysts are late-stage tailoring enzymes that modify natural
products. PTs catalyze the attachment of prenyl moieties to natural product acceptors using
pyrophosphate donors. This prenyl modification in small molecules leads to changes in
structural and biological activities. Understanding the structural insights as well as the
mechanisms by which PTs function allows us to utilize PTs as a unique approach towards
drug development. PriB PT is an example of aromatic PTs that has been characterized
previously as a L-tryptophan (L-Trp) C6 C-prenyltransferase (C6-C-PT). Analysis of PriB
binding pocket, highlighted key residues that might play an important role in determining
the regiospecificity of the enzyme and their mechanisms. Hence, we hypothesized that sitedirected mutagenesis of one of these residues will alter the enzyme regiospecificity and/or
its permissiveness leading to variation in the pharmacokinetics and biological activities of
small molecules. Site-directed mutagenesis approach was used to engineer PriB PT as a
model for C6-PTs and the purified mutant proteins were produced and purified. In vitro
reactions of the purified engineered proteins have shown altered regiospecificity toward
substrate acceptors when compared to wild type. The long-term goal for this study is to
utilize the permissiveness of PriB enzyme for drug diversification and determine the
activity of the mutant PriB enzymes. This study will also shed some light on the
mechanistic insights of aromatic C6-PTs.

vii

TABLE OF CONTENTS
CHAPTER 1

1

INTRODUCTION
CHAPTER 2

16

METHODS
CHAPTER 3

22

RESULTS and DISCUSSION
CHAPTER 4

35

CONCLUSION
REFERENCES

36

viii

LIST OF TABLES
Table 1. The mutants PriB_H312, and 6-DMATSx designed primers………………… 17
Table 2. Summary of histidine and tyrosine mutations on ArPTs……………………… 31

ix

LIST OF FIGURES
Figure 1. The catalyzed reaction of aromatic PTs ..............................................................4
Figure 2. Leaving of OPP group lead to carbocation intermediate on C1 or C3 .................5
Figure 3. Examples of prenylated active compounds .........................................................7
Figure 4. Examples of prenylated flavonoids that showed anticancer activity ...................9
Figure 5. The X-ray ternary crystal structure of PriB enzyme with substrates .................13
Figure 6. The binding pocket of PriB ...............................................................................14
Figure 7. His 312 residue in PriB active site.....................................................................14
Figure 8. The catalyze reaction of PriB, and the hypothetical reaction for mutant PriB ..15
Figure 9. Structure alignment of indole PTs .....................................................................15
Figure 10. The sequencing results of some amino acids (Lys, Trp). ................................22
Figure 11. FPLC elution profile of PriB_H312Y crude protein .......................................23
Figure 12. SDS-PAGE of purified PriB and their mutants ...............................................23
Figure 13. HPLC analysis of the PriB_H312X-mutants (other than Tyr) ........................25
Figure 14. HPLC identification of the enzyme products of PriB and H\Y mutant ...........26
Figure 15. HPLC identification of the enzyme products from the large scale reaction ....26
Figure 16. LC-MS spectra of PriB WT and PriB_H312Y ................................................27
Figure 17. Structure alignment analog of PriB and 6-DMATSxx (Sa, Sv, Mo) ......................28
Figure 18. SDS-PAGE of purified 6-DMATSx PTs and their mutant’s proteins.............29
Figure 19. HPLC identification of the enzyme products of 6-DMATSxx (Sa, Sv, Mo) ........30
Figure 20. Theoretical enzymatic catalysis of DMATS in PriB .......................................33
Figure 21. Residues that could contribute to reaction catalysis of PriB and FgaPT2 .......33
Figure 22. Structure analog of mutation of His312 to Tyr................................................34

x

Chapter 1
INTRODUCTION
1.1. The Progress of Natural Products Discovery
Natural products (NPs), have been used as different treatment options for many severe diseases.
The majority of the active ingredients of medicines are obtained from natural sources, such as
plants, animals, fungi, and microorganisms (Newman & Cragg, 2016). The diversity in the
chemical structures and the efficacy of NPs have served as essential approaches to understanding
the cell physiology (Wilkinson & Micklefield, 2007). Many pharmaceutical companies, during the
last few decades, have shifted to synthetic compounds rather than NPs in drug discovery due to
several limitations including traditional NPs screening techniques which frequently led to the
rediscovery of already known compounds and inconsistency of NP production from their natural
sources. Furthermore, the minute quantities of NPs obtained from their natural sources, which
requires large quantities of the original source, high labor costs for extraction and purifications, as
well as time-consuming processes are additional hurdles. Moreover, the complexity of natural
products makes the characterization of their structures a challenging task not preferable for
medicinal chemists (Lam, 2007).

Nevertheless, the innovation of NP discovery methods, such as new methodology in production,
purification, and characterization, has influenced numerous pharmaceutical industries to regain
interest in this field. Furthermore, with the development of new screening assays and targets
combined with the new chemical entities that NPs provide, have increased the interest in NP
discovery (Katz & Baltz, 2016). For example, Novartis Institutes for BioMedical Innovation
techniques led to the discovery of novel bioactive compounds, such as anticancer Englerin A,
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Argyrin B, and antibacterial antiparasitic. Cyclomarin A (Schmitt et al., 2016). Mutational
biosynthesis also is another approach for the development of novel NPs through the insertion of
analogs of NP intermediates into biosynthetic pathways; for instance, the production of
nikkomycin antibiotic from novobiocin analogs (Weist & Süssmuth, 2005).

During the last three decades, there have been two fundamental scientific progressions that had an
essential impact on NP discovery. These advancements, include the detailed understanding of NP
biosynthesis, and the development of genetic tools for Streptomycetes. The diverse NP structures
are synthesized through a complex system of enzymatically catalyzed metabolic pathways.
Enzymes from natural product biosynthetic pathways have become fascinating approaches for
modifying the bioactivities of these complex molecules especially after the evolution of NPs
biosynthesis technology and the identification of biosynthetic gene clusters and encoding enzymes
(Ncube et al., 2017) (Medema et al., 2015). In addition, Streptomycetes have exposed a significant
and adjustable group of bacteria for the production of diverse valuable secondary metabolites.
These secondary metabolites have brought attention in numeral medicinal companies and
academia after the development of recombinant DNA (rDNA) technology. These advancements
include plasmid vectors, protoplast transformation, and engineering strategies as well as the
development of analytical approaches such as proteomics and metabolomics (Bekker et al., 2014)
(Bro & Nielsen, 2004) (Katz & Baltz, 2016). Improvement of DNA cloning and sequencing have
assisted in understanding the biochemical pathways of NPs via resolving and predicting the
enzymes that are involved in the biosynthesis from NPs genes sequences or gene cluster.
Clustering enables the cloning of the whole NP biosynthesis pathway into vectors and heterologous
hosts and the production of NPs combinatorial biosynthesis.
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Combinatorial biosynthesis is a method to manufacture a sequence of elected potential drugs for
high-throughput screening. This approach has been used for the generation of “unnatural” NPs
especially those biosynthesized by nonribosomal peptide synthetase (NRPS) and polyketide
synthase (PKS) genes, which are involved in the biosynthesis of polyketides (PKs) and
nonribosomal peptides (NRPs), respectively, possess essential antibiotic, anticancer, and
immunosuppressant activities (Menzella & Reeves, 2007) (Yin et al., 2007) (Weissman, 2015).

1.2. Tailoring Enzymes and Chemoenzymatic Reactions
The decoration of NPs by chemical moieties such as hydroxyls, methyls, sugars, and halogens is
crucial for the modification of these compounds and leads to the enhancement of their
pharmacological activities and properties. These groups are added by a group of enzymes that are
encoded within the biosynthetic gene cluster of the NP and are collectively called tailoring
enzymes.

Enzymes,

such

as

methyltransferases,

cytochrome

P450s,

halogenases,

glycosyltransferases, prenyltransferases, are examples of tailoring enzymes (Lin et al,. 2012).
Tailoring enzymes can be utilized as valuable tools for the targeted modification of molecules and
drugs and can complement chemical methods to generate novel compounds (Alwaseem et al,.
2018) (S. Mori et al,. 2019) (Newmister et al., 2018) (Hughes et al., 2017).

Enzyme catalysis is one of the powerful tools to modify small molecules and has become
frequently used in the chemical industry and scientific research due to multiple reasons.
Biocatalysts are efficient, usually produce regiospecific products, under greener, milder, and safer
conditions for the modification of bioactive compounds (González-Sabín et al., 2011) (Wells et
al., 2012). Enzymes are highly efficient and catalyze specific reactions often with high yield in
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aqueous conditions with minimum side products (Romney et al, 2018). Chemoenzymatic
reactions, enzymatic modification, along with synthetic methods, has succeeded to produce
biologically active compounds such as analogs of the antibiotics daptomycin, vancomycin, and
pristinamycin (Grünewald & Marahiel, 2006).

1.3. Prenyltransferase Enzymes
Prenyltransferase (PT) biocatalysts are tailoring enzymes used to catalyze the attachment of prenyl
moieties from pyrophosphate substrates (donors) to various aliphatic or aromatic acceptors via
nucleophilic substitution (Figure 1). Examples of natural pyrophosphate donor substrates include
the pyrophosphates of dimethylallyl (DMAPP, C5), geranyl (GPP, C10), farnesyl (FPP, C15), or
geranylgeranyl (GGPP, C20). Acceptor substrates include low and high molecular weight small
molecules, nucleic acids, peptides, and proteins (Winkelblech, Fan, & Li, 2015). Furthermore,
protein prenyltransferases are significant for the post-translational modification of proteins in
living organisms and demonstrate essential drug targets (Heide, 2009).

Figure 1. The catalyzed reaction of aromatic PTs

The SN1 reaction of dimethylallyl pyrophosphate (DMAPP) is initiated by the release of the
pyrophosphate moiety as a good leaving group and the cleavage of carbon-oxygen (C1-OPP) bond
leading to cationic intermediates. This cationic intermediate is stabilized by charge resonance over
4

C1 and C3 of the prenyl group (Figure 2). The prenyl cation attaches to the nucleophiles in the
indole ring (acceptor) via C1 or C3 to form normal and reverse prenylation, respectively (Walsh,
2014).
OPP

+

OPP

DMAPP

Figure 2. Release of OPP group lead to carbocation intermediate on C1 or C3

Dimethylallyltryptophan synthase (DMATS) superfamily are aromatic PTs (ArPTs) and is one of
the most investigated enzyme subgroups. They share sequence homology with the DMATSs
involved in the biosynthesis of ergot alkaloids in Claviceps purpurea (Tsai et al., 1995). Until
2015, more than 40 such enzymes have been determined and characterized biochemically
(Winkelblech et al., 2015). The majority of the DMATS superfamily members are involved in the
biosynthesis of prenylated indole alkaloids and modify indole derivatives as acceptors including,
tryptophan and tryptophan-containing cyclic dipeptides as substrates (Winkelblech et al., 2015).
One interesting feature of DMATSs and other ArPTs is their relatively broad acceptor
permissiveness allowing them to accommodate various substrates. Thus, using these enzymes in
drug modification could, in some instances, provide a more efficient and environmentally friendly
approach alternative to synthetic modification (Fan & Li, 2013).
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1.4. Importance of Prenylation and Regiospecificity
Many published studies demonstrated the bioactivity of prenylated natural products (Alhassan et
al., 2014). The advantages of the presence of a prenyl moiety in various natural compounds include
enhancing the target protein binding affinity as well as improving the interaction with cell
membrane/cell wall compared to the nonprenylated counterparts (Botta et al., 2005). Prenylation
in small molecules leads to changes in structural and biological activities. Prenylation opens the
door for a unique approach towards drug development and provides new chemical libraries for
pharmacological screening (Botta et al., 2005). Biosynthesis of many biologically active
compounds in animals and plants depends on aromatic secondary metabolite prenylation (Alhassan
et al., 2014). Examples of prenylated bioactive compounds include novobiocin, clorobiocin,
fumigaclavine C, fumitremorgin B, sophoraflavanone G, cyclomarin C, and roquefortine C (Figure
3).
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Figure 3. Examples of prenylated active compounds

One study examined the antiproliferative activity of nonprenylated naringenin and prenylated
flavonoids [(Xanthohumol and four prenylflavonoids: 8-prenylnaringenin, 6-prenylnaringenin
isoxanthohumol, and α,β-dihydroxanthohumol) (Figure 4)] against different human cancer cell
line (Bartmańska et al., 2018). The outcome of this study exhibited that prenylated naringenins
had higher anticancer activity compared to nonprenylated naringenin. Moreover, this study pointed
out the significance of the position of prenylation, where there were changes in activity and
specificity between 6-prenyl- and 8-prenylnaringenin. The C-8 isomer showed higher
7

antiproliferative activity, except breast cancer cell line, where 6-prenyl analog exhibited higher
activity and selectivity (Bartmańska et al., 2018). Furthermore, other previous study showed that
adding prenyl group to the cyclic lipopeptide antibiotic daptomycin increased the antimicrobial
activity against gram-positive bacteria compared to nonprenylated daptomycin (Elshahawi et al.,
2017). Furthermore, the mode of prenylation, normal versus reverse, also affects the activity of the
drugs (Elshahawi et al., 2017).

Another advantage of PTs is their ability to catalyze carbon-carbon bond formation. Generally,
different PTs have been characterized as capable of catalyzing the transfer of the prenyl moiety to
all carbon positions of the indole ring. Noticeably, PTs catalyze the formation of a carbon-carbon
bond between the indole ring and the prenyl group in milliseconds (Tanner, 2015). Carbon-carbon
bond formation in organic synthesis is a crucial step to build up complex structure compounds
from smaller molecules. Generating complex products have tremendous applications.
Nevertheless, it is very challenging to approach this via synthetic methods because it requires
intricate approaches for chiral synthesis (for non-aromatic moieties), multiple protection and
deprotection steps as well as high temperature and pressure requirement (Schmidt et al., 2016).
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Thus, this indicates the significance of prenyl moieties for improving the pharmacological activity
for many natural products and utilizing PTs to modify drugs.
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Figure 4. Examples of prenylated flavonoids that showed anticancer activity

1.5. Enzyme Engineering
Biochemical reactions in aqueous media are fundamental for life; however, in synthetic chemistry,
the existence of water in chemical reactions could lead to negative impacts, including minimizing
yields and productivity. Certainly, removing even minute quantities of water from chemical
reactions is sometimes a challenging task for most chemists (Arnold, 2018). Most reactions in
chemical syntheses require organic solvents, which produce toxic wastes that affect safety and the
environment. Therefore, replacement of reactions running in organic solvents with substitutes that
work in aqueous media is a hot topic in research. Moreover, water-based reactions provide an
essential boundary between chemistry and biology, which allow making chemical modifications
of biomolecules. This leads to the improvement of biotherapeutic medicines such as bioactive
peptides, drug conjugated antibody, biopharmaceuticals, and small molecule derivatives from
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natural products. Mainly, none of these accomplished would be achievable without aqueous
reactions because most biological molecules are unstable and insoluble in organic media (Romney
et al., 2018).

Recently, several pharmaceutical and biotechnological industries started incorporating natural
enzymes for many fundamental reactions. Yet, many natural biocatalysts do not exhibit the desired
stability and efficiency to proceed with the industrial requirements (Kokkonen et al., 2019).
Nowadays, the advancement of biotechnology has brought new techniques to improve and produce
enzymes with desirable properties. Protein engineering such as site-directed mutagenesis is one of
the approaches that can alter amino acids residues at specific enzyme sites. In the last two decades,
enzyme engineering has succeeded in modifying enzymes with higher activities than wild-type
enzymes (Bilal et al., 2018). Furthermore, enzyme engineering demonstrated the ability to improve
the stability and catalytic activity towards non-native substrates (Bornscheuer et al., 2012)
(Almhjell et al., 2018). Enzyme engineering has also led to catalyzing reactions that were restricted
only by synthetic catalysts (Hammer et al., 2017) (Zhang et al., 2019). Various engineered
enzymes have exhibited significant improvement in selectivity and activity during biological
reactions (Hammer et al., 2017) (Cho et al., 2019).

Previous studies on the PTs engineering showed that site-directed mutagenesis on some PT amino
acid residues changed the catalytic activity and improved the acceptance of other substrates. One
study published in 2017 showed that site-directed mutagenesis of a DMATS superfamily member,
FtmPT1 (Gly115 and Tyr205 to other residues), led to altering the prenylation position and
increase of permissiveness towards nonnative acceptors (Zhou et al., 2016). Another study
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published in 2015, demonstrated that a mutant FgaPT2 (Lys174 to Phe) had altered the substrate
preference (L-Trp) to another substrate, L-Tyr (Fan et al., 2015).

Other researches have also studied the role of other active site residues to improve the substrate
permissiveness, Fan and colleagues have shown enhancing the activity of aromatic
prenyltransferase FgaPT2 acceptance toward cyclic dipeptide substrate, R244 has been replaced
with other amino acids. Notably, mutation of R244 with amino acid leucine significantly improved
the product yield with cyclic dipeptide substrate comparing with other mutants; however, the result
of R244 mutants which tested with the native substrate L-Trp decreased or abolished the activity.
Clearly, this outcome showed the importance of R244 as a key residue to maintain the L-Trp
substrate by hydrogen bonding to the carboxylate group of L-Trp (Fan & Li, 2016). Moreover, in
a previous study, site-directed mutagenesis on TleC and MpnD aromatic PTs have changed the
enzyme activity and the preferences of prenyl group length of the substrate. The structural analysis
of the binding pocket of both enzymes demonstrated that Trp97, Ala173 in TleC have replaced
with Tyr80, Met159 in MpnD. In TleC, mutation of Trp97 to Tyr and Ala173 to Met have affected
the donor preferences comparing with TleC wild-type. The Trp97 to Tyr replacement enhanced
the activity of C5 DMAPP substrate preferences than the preferred donor C10 GPP. Moreover, the
Ala173 Met mutant increased the acceptance toward C5 DMAPP, whereas C10 GPP is no longer
accepted. In MpnD PT mutation of Tyr80 to Trp and Met159 to Ala increased the C10 prenylation
and whereas the prenylation of C5 decreased compared with wild-type (T. Mori et al., 2016).
Structure alignment of PriB PTs with the other previous studied PTs have shown similarity among
them. This suggests that to perform alteration of substrate (donors/ acceptors) selectivity for PriB,
mutagenesis based on the previously mentions studies could be performed.
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1.6. PriB Prenyltransferases
PriB PT is an aromatic PTs that was characterized from the genome of a bacterial strain
Streptomyces sp. (actinomycetes), which was separated from the soil near a thermal vent of Ruth
Mullins coal fire in the Appalachian Mountains (Elshahawi et al., 2017; Wang et al., 2015). PriB
protein belong to the DMATS superfamily characterized with a barrel shape (β-barrel) composed
of αββα units. The PriB is composed of a cylindrical β-sheet arranged around a ring of solventexposed α-helices (Figure 5) (Elshahawi et al., 2017). PriB was characterized as an L-Trp C6 Cprenyltransferase (C-PT) (Elshahawi et al., 2017, Fan, Winkelblech, & Li, 2015). PriB’s
permissiveness is not limited to acceptors but also extends to donor substrates. PriB is one of few
DMATS enzymes that is capable of accommodating not only DMAPP and L-Trp (native donor
and acceptor, respectively), but also various non-native donors (geranyl, farnesyl, geranylgeranyl
and other synthetic diphosphates) and other aromatic acceptor substrates including, anthranilic
acid, naphthalenes, anthraquinones, phenazines, and D-Trp with high conversion percentages. PriB
PT was also found to prenylate the drug pindolol (Visken®) and the antibiotic daptomycin
(Cubicin®) producing a derivative with higher activity (Elshahawi et al., 2017).

12

Figure 5. The X-ray ternary crystal structure of PriB enzyme with substrates, L-Trp (acceptor) and DMSPP (donor
analog) in yellow sticks

In this study, the examination of the binding pocket of PriB X-ray crystal structure (Figure 6)
showed that both the native donor and acceptor are in proximity with multiple residues including
His312, Tyr380, Leu110, Trp165, Tyr181, Tyr364, Arg316, Phe220, and Leu293.

A basic amino acid residue suggests that it could be playing a role in the catalysis of the C6
nucleophilic substitution reaction (Murakami et al., 2006; Guillén Schlippe & Hedstrom, 2005;
Metzger et al., 2009). Furthermore, we determined that the closest position of the nitrogen atom
of the imidazole ring of His312 is with C6 L-Trp (3.7 Å) (Figure 7). Also, the structure alignments
of PriB with other non C-6 PTs, AnaPT (C3-reverse, PDB ID 4LD7) TleC (C7-reverse, PDB ID
4YZL), MpnD (C7-reverse, PDB ID 4YLA), FgaPT2 (C3-normal, PDB ID 3I4X), FtmPT1(C2normal, PDB ID 3O2K), and CdpNPT (C3-reverse, PDB ID 4E0U) showed the H312 in PriB are
aligned with Tyr residues in these enzymes (Figure 9). Thus, we propose that site-directed
mutagenesis of PriB His312 residue into other amino acid residues will alter the enzyme
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regiospecificity. The goal of this work is to investigate the role of His312 in the regiospecificity
of PriB and other C-6 indole PTs. This work will also shed some light on the mechanistic insights
of aromatic PTs and other C-6-C-PTs, and the outcome of this study would be to utilize the altered
regiospecificity.

Figure 6. Exhibit close up view of the binding pocket, the binding pocket shows that both L-Trp and DMSPP
(yellow sticks) in close proximity to each other and to PriB multiple residues (purple sticks).

Figure 7. Show the nearest position of nitrogen atom of imidazole ring in His312 residue is with C6 L-Trp (3.7 Å).
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Figure 9. Structure alignment of PriB (C6-normal, PDB ID 5INJ), AnaPT (C3-reverse, PDB ID 4LD7) TleC (C7reverse, PDB ID 4YZL), MpnD (C7-reverse, PDB ID 4YLA), FgaPT2 (C3-normal, PDB ID 3I4X), FtmPT1(C2normal, PDB ID 3O2K), and CdpNPT (C3-reverse, PDB ID 4E0U) indole PTs showing conserved His312 in C-6-CPTs representing another evidence of the involvement of His312 residue in the C6 prenylation regiospecificity. The
crystal structures of PTs have been downloaded from Protein Data Bank, www.rcsb.org
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Chapter 2
METHODS
2.1. Strains and Materials
PriB plasmid was obtained as a gift from the University of Kentucky, Center for Pharmaceutical
Research and Innovation, Natural Products Repository. E. coli 5α and BL21 (DE3) competent cells
were purchased from New England Biolabs. All reagents and chemicals were purchased from
Sigma-Aldrich or Fisher Scientific. LB Broth (Miller) and LB Broth with agar (Lennox) were
obtained from Sigma Aldrich (St. Louis, Missouri). DNA primers were obtained from Integrated
DNA Technologies, Inc. (Coralville, Iowa). All mutations were sequence verified at Retrogen, Inc
(San Diego, California) or ACGT, Inc (Wheeling, Illinois). Gene analysis and alignments were
performed using Geneious 11.1.5.

2.2. Plasmid Purification
The PriB plasmid was transformed into E. coli 5α cells and streaked on a plate containing LB agar
and kanamycin with final concentration 80 µg mL-1. The transformed cells were incubated at 37°C
for 16 hr followed by inoculation into liquid medium (LB broth with kanamycin) at 37°C with 250
rpm for 16 hr. The cell pellet was collected by centrifugation at 4,500 ×g for 10 min. Genomic
DNA was purified using Monarch® Nucleic Acid Purification Kits (New Englands BioLabs®)
following the manufacturer’s protocol. DNA quality and quantity were assessed using gel
electrophoresis and Nanodrop (Thermo Scientific NanoDrop 2000 1-position Spectrophotometer).

2.3. Site Directed Mutagenesis
In order to perform site-directed mutagenesis, the primers of PriB_H312 were designed using
NEBase Changer tool, as shown in Table 1 and were used for mutagenesis. Q5® Site-Directed
16

Mutagenesis Kit (New Englands BioLabs®) was performed following the manufacturer’s protocol
and transformed into 5α cells. Purified plasmids were isolated, purified and quantified. Quality of
purified plasmids were assessed by measuring the A260/280 and A260/230. Plasmids of suitable
quantity and high quality were sent for DNA sequencing. The correct plasmids, as confirmed by
sequencing, were transformed into BL21(DE3) incubated onto LB agar with kanamycin (80 µg
mL-1) plates and incubated overnight at 37°C. After checking the cells growth, one colony from
each strain was inoculated into 15 mL culture tube containing 4 mL liquid medium (LB with
kanamycin, 80 µg mL-1) and incubated for 16 hr, at 37°C, 250 rpm. Glycerol stocks of each
construct containing 15% glycerol were stored in at −80°C for future use.

Table 1. Designed primers in order to mutate PriB_H312. Residues targeting His312 residue are underlined.

DNA Primer

Sequences

PriB_H312A-F

5’-CTA CAC CCT CGC TGT GCC GGT CCG CGA CTA CGT CCG G-3’

PriB_H312R-F

5’-CTA CAC CCT CAG AGT GCC GGT CCG CGA CTA CGT CCG-3’

PriB_H312N-F

5’-CTA CAC CCT CAA TGT GCC GGT CCG CGA CTA C-3’

PriB_H312D-F

5’-CTA CAC CCT CGA TGT GCC GGT CCG CGA CTA C-3’

PriB_H312C-F

5’-CTA CAC CCT CTG TGT GCC GGT CCG CGA CTA CGT CCG G-3’

PriB_H312Q-F

5’-CTA CAC CCT CCA AGT GCC GGT CCG CG-3’

PriB_H312E-F

5’-CTA CAC CCT CGA AGT GCC GGT CCG CGA CTA CG-3’

PriB_H312G-F

5’-CTA CAC CCT CGG TGT GCC GGT CCG CGA CTA CGT CCG G-3

PriB_H312I-F

5’-CTA CAC CCT CAT TGT GCC GGT CCG CGA CTA CGT CCG G-3’

PriB_H312L-F

5’-CTA CAC CCT CTT AGT GCC GGT CCG CGA CTA CGT CCG G-3’

PriB_H312K-F

5’-CTA CAC CCT CAA AGT GCC GGT CCG CGA CTA C-3’
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PriB_H312M-F

5’-CTA CAC CCT CAT GGT GCC GGT CCG CGA CTA CGT CCG GCA CGA CGG3’

PriB_H312F-F

5’-CTA CAC CCT CTT TGT GCC GGT CCG CGA CTA CGT CCG G -3’

PriB_H312P-F

5’-CTA CAC CCT CCC TGT GCC GGT CCG CGA CTA CGT CC-3’

PriB_H312S-F

5’-CTA CAC CCT CTC AGT GCC GGT CCG CGA CTA CGT CCG GCA C-3’

PriB_H312T-F

5’-CTA CAC CCT CAC TGT GCC GGT CCG CGA CTA CGT CCG GCA C-3’

PriB_H312W-F

5’-CTA CAC CCT CTG GGT GCC GGT CCG CGA CTA CGT CCG G-3’

PriB_H312Y-F

5’-CTA CAC CCT CTA TGT GCC GGT CCG CGA C-3’

PriB_H312V-F

5’-CTA CAC CCT CGT AGT GCC GGT CCG CGA CTA CGT CCG GCA CG -3’

PriB_H312X-R

5’-CCG CTG GGC CGC CCG GTC-3’

6DMATSsa_H284Y-F

5’-CTT TAC CTT GTA TAT TCC GGT TCG TGA TTA TG-3’

6DMATSsa_H284Y-R

5’-CCG CTC GGA CGA CCA CTG-3’

6DMATSsv_H287Y-F

5’-TTA TAC GCT GTA TGT TCC CGT AAG-3’

6DMATSsv_H287Y-R

5’-CCA GAA GGA AGG CCA GTT-3’

6DMATSmo_H329Y-F

5’-TCT GAT CGC GTA TGT TTC TCT GCG-3’

6DMATSmo_H329Y-R

5’-CCA ACA CCG TCA CGC AGC-3’

6DMATSmo_Y277H-F

5’-TTA CTC TAT CCA TGT TCC GAT CCG TTC TTA CGT TAC C-3’

6DMATSmo_Y277H-R

5’-CCA ACC GGA CGG TCC GCA-3’

2.4. Protein Production
LB broth (1L) supplemented with kanamycin (80 µg mL-1) was inoculated with 0.3% (v/v) of an
overnight PriB_H312_X (Phe, Lys, Arg, Trp, Tyr) E. coli BL21 (DE3) at 37°C with shaking (250
rpm). Cultures were induced at OD600 of ~ 0.6–0.8 with isopropyl-β-D-thiogalactopyranoside
(IPTG, 0.5 mM final concentration) and allowed to grow for an additional 16 hr at 23°C. The cells
were centrifuged, harvested and stored at −80°C until used. The proteins of other mutant
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PriB_H312 plasmids were expressed following the same procedure, but on a small scale using 250
mL baffled flasks containing 100 mL LB/kanamycin.

2.5. Protein Purification
All following steps were carried out on the ice. Cells were allowed to thaw then subsequently lysed
by sonication (Virtis VirSonic 475 with a microtip, 100W, 10 × 10 sec pulses, 20 sec between
pulses). Insoluble debris was removed by centrifugation at 15,000 ×g for 1 hr. The supernatants
were collected and filtered using 0.22 µm filters, and the desired N-His6-PriB mutant fusion
proteins were purified via HiTrap nickel-nitrilotriacetic acid (Ni-NTA, Sigma) affinity
chromatography using standard protocols with NGC™ 10 Medium-Pressure Chromatography
Systems (BIO-RAD). Buffer exchange of each sample were performed using a PD-10 column (GE
Healthcare) eluted with 50 mM Tris, 100 mM NaCl, pH 8.0 to yield the desired mutant PriB
proteins. Fractions were collected and concentrated using Amicon Ultra Centrifuge columns
30,000 MWCO (EMD Millipore) and stored in 50 mM Tris, 100 mM NaCl, glycerol 10%, pH 8.0
at −80°C. Protein concentrations were determined by Bradford assay (Bio-Rad) using bovine
serum albumin as a standard. Purity and presence of proteins were confirmed by SDS-PAGE gel
(Blot™ 4-12% Bis-Tris Plus, Invitrogen) electrophoresis. The images of the gels were taken by
ChemiDocTM Imaging system (Bio-Rad).

2.6. HPLC Methods
HPLC Method A—The method was developed on Shimadzu UHPLC (RX-SHMADZU-9020Instrument). SUPELCO® Titan C-18 (1.9 µm, 15 cm × 2.1 mm) column (Sigma-Aldrich) [7% B
for 2 min, gradient of 7% to 100% B for 6 min, 100% B for 3 min, 100% B to 7% B over 20
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second, 7% B for over 4 min (A = ddH2O with 0.1% formic acid; B = acetonitrile with 0.1%
formic acid) flow rate = 0.4 mL/min; A280]. Injection volume 20 µL.
HPLC Method B —The method was developed on Bruker Q-TOF LC/MS (HPLC). SUPELCO®
Titan C-18 (1.9 µm, 5 cm × 2.1 mm) column (Sigma-Aldrich) [7% B for 2 min, gradient of 7% B
to 100% B for 5 min, 100% B for 3 min, 100% B to 7% B for 20 second, 7% B for over 4 min (A
= ddH2O with 0.1% formic acid; B = acetonitrile with 0.1% formic acid) flow rate = 0.4 mL/min;
A280]. Injection volume 10 µL.
HPLC Method C— The method was developed on Shimadzu analytical HPLC (Prominence i,
LC-2030 3D). Supelco Ascentis® C-18 (5 µm, 25 cm × 10 mm) column (Sigma-Aldrich) [17% B
for 140 min, isocratic, (A = ddH2O with 0.1% formic acid; B = acetonitrile with 0.1% formic acid)
flow rate = 4 mL/min; A280].

2.7. In Vitro Characterization of Mutant Proteins
Mutant PriB in vitro assays were conducted in PCR tubes (200 µL) in a volume of 25 µL Tris 50
mM (pH 8.0) containing a final concentration of 0.5 mM L-Trp, 0.5 mM DMAPP, and 1 µM PriB
mutant. After pre-incubation of the reaction mixture at 37°C for 10 min, the reactions were initiated
by the addition of enzyme and allowed to proceed for 16 hrs at 37°C. Reactions with positive and
negative reactions with and without the wild type of PriB respectively were performed under the
same conditions. The reactions were quenched by the addition of 25 µL MeOH and mixing
followed by centrifugation (22,000 ×g, 15 min, 4°C) to remove precipitated protein. The
supernatants were analyzed by HPLC-PDA using Method A and mass using Method B were used
to calculate conversion rate based on the area of the substrate and the prenylated product peaks.
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2.8. Large Scale in Vitro Reaction for Mutant Protein
For isolation and full characterization of prenylated L-Trp analogs, 1 mL reactions (×50) in 1.5 mL
Eppendorf tubes containing 2.5 mM acceptor (L-Trp), 2.5 mM DMAPP, 12.5 µM mutant enzyme
in 50 mM Tris (pH 8.0) were incubated for 16 hr at 37°C. Reactions were combined, terminated
by mixing with an equal volume of MeOH, centrifuged to remove precipitated protein and dried
under reduced pressure.

2.9. Generation of 6-DMATSxx Mutants
Codon optimized constructs of 6-DMATSMo, 6-DMATSSa, and 6-DMATSSv were synthesized by
Twist Bioscience (San Francisco, CA) and ligated into pET28a plasmids. Plasmids were purified
as described with PriB. Site-directed mutagenesis was performed in the active site of other C-6
ArPTs including 6-DMATS Sa_H284Y, 6-DMATS Sv_H287Y, and 6-DMATSMo (Y277H, H329Y,
and double mutant Y277H_H329Y). The corresponding 6-DMATSxx proteins were produced and
purified with the same methods described for PriB-H312X mutants. Proteins production were
qualitatively and quantitatively assessed as described previously.
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Chapter 3
RESULTS and DISCUSSION
3.1. Site Directed Mutagenesis
Saturation mutagenesis has been performed on PriB_H312 to mutate it to all other 19 amino acid
residues. Thus we obtained PriB_H312X where X = Ala (A), Cys (C), Asp (D), Glu (E), Phe (F),
Gly (G), Ile (I), Lys (K), Leu (L), Met (M), Asn (N), Pro (P), Gln (Q), Arg (R), Ser (S), Thr (T),
Val (V), Trp (W) & Tyr (Y). The DNA mutants of the mutated PTs were confirmed by DNA
sequencing (Figure 10).

Figure 10. Representative sequencing results of some amino acids (Lys, Trp) showing successful mutations.

3.2. Protein Production and Purification
Attempts to produce all 19 PriB_H312X mutants were performed followed by purification using
Ni-NTA resin column (Figure 11). The mutant proteins culture yield (other than Tyr mutant) were
between 2 – 5 mg L-1. The final concentrations of the mutated proteins were between 8 – 12 mg
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mL-1. The PriB mutant proteins were analyzed by SDS-PAGE (Figure 12). Only two mutants
(PriB_H312D and PriB_H312P) did not show the protein bands. This lack of protein production
indicates possible toxicity or stability issues. The molecular weight of the PriB was consistent with
the calculated weight (43.34 kDa).

Figure 11. FPLC elution profile of PriB_H312Y crude protein. Column (Ni-NTA, Sigma) affinity chromatography.
Buffer A: 10 mM Imidazole, 50 mM KH2PO4, 300 mM NaCl (pH 8.0). Buffer B: 250 mM Imidazole, 50 mM KH2PO4,
300 mM NaCl (pH 8.0). Flow rate: 1 mL/min

Figure 12. Analysis of the overproduced and purified PriB, and their mutants on SDS-PAGE
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3.3. In Vitro Characterization of Mutant Proteins
HPLC analysis of the incubation mixture of L-Trp, DMAPP with PriB_H312Y protein showed
that the enzymatic reaction produces more than one product in contrast to wild-type PriB which
produces only one product 6-dimethylallyltryptophan (6-DMAT) (Figures 14 and 15) as previously
reported (Elshahawi et al., 2017). Other PriB_H312X either lacked activity or produce minimal
conversion than wild type except for PriB_H312X (G, E, and Q) where their conversion yield
similar to wild type (Figure 13). Figure 16 exhibited LC-MS data of PriB (WT) and PriB_H312Y
prenylated compound. The chromatogram PriB WT shows only one compound eluted at 5.7 min
with observed mass [M+H]+ 273.1602, whereas the PriB_H312Y shows 3 compounds in different
retention time 5.3 min, 5.4 min, and 5.7 min, with observed mass [M+H]+ 273.1588, 273.1596,
and 273.1596 respectively. The molecular weight for the prenylated product is 272.1525.
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PriB_H312W
PriB_H312V
PriB_H312T
PriB_H312S
PriB_H312R

PriB_H312Q
PriB_H312P
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Figure 13. HPLC analysis of the PriB_H312X-mutants (other than Tyr) products, showed no new products
other than C-6 prenylated products using Method A
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0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2

PriB_H312Y

0.1
0.0
-0.1

4.50

0.0

uV (x10,000)

1.0

2.0

3.0

4.0

5.0

6.0

7.0

8.0

9.0

10.0

11.0

12.0

13.0

4.25
4.00
3.75
3.50
3.25
3.00
2.75
2.50
2.25
2.00
1.75
1.50
1.25
1.00
0.75
0.50
0.25
0.00
0

10

20

30

40

50

60

70

80

90

100

110

120

130

min

Figure 15. The enzyme products from the large-scale reaction was isolated and injected to HPLC (17% ACN, 0.1%
FA for 140 min) to separate and collect the compounds using Method C
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3.4. Q-TOF Mass (LC-MS)

Figure 16. LC-MS spectra of PriB-WT and PriB-H312Y showed that the PriB-WT has only 1 prenylated compound
with mass [M+H]+ 273.1602. PriB-H312Y showed 3 compounds in different retention times (5.3 min, 5.4 min, and
5.7 min) with mass [M+H]+ (273.1588), (273.1596), and (273.1596) respectively, using Method B.

27

3.5. Analysis of Binding Pockets of other C-6 PT
To see if the switch of the His residue to Tyr will provide the same results in other C-6-indole PTs
could lead to the same PriB_H312Y results. Three C-6-indole PTs including 6dimethylallyltryptophan

synthase

from

bacteria

S.

ambofaciens

(6-DMATSSa),

6-

dimethylallyltryptophan synthase from bacteria S. violaceusniger (6-DMATSSv), and
dimethylallyltryptophan synthase from bacteria M. olivasterospora (6-DMATSMo) were reported
previously (Winkelblech & Li, 2014) (Winkelblech, Xie, & Li, 2016). However, no crystal
structures are deposited in PDB. Thus, we generated homology models for the three proteins using
SWISS-MODEL software. The structural alignment of these C-6-PTs have shown that His312
residue in PriB corresponds to H284 and H287 in 6-DMATSSa and 6-DMATSSv, respectively, but
it corresponds to Y277 in 6-DMATSmo. However, 6-DMATSMo has a His residue in the binding
pocket (H329) which aligns with Tyr in the other analyzed 6-PTs (Figure 17).

A

B

C

Figure 17. Structural alignment of PriB and homology models of 6-DMATSSa, 6- DMATSSv, and 6-DMATSMo. (B) A
close up of His312 residue in PriB, and corresponding residues in other 6-DMATS enzymes showing the presence of
His in 6- DMATSSa and 6-DMATSSv but Tyr in 6-DMATSMo. (C) Histidine residue in 6-DMATSMo aligns with a Tyr
residue in the different region
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3.6. Mutation of other C6-C-PTs
Site-directed mutagenesis was performed in the active site of other C-6 ArPTs including 6DMATSSa_H284Y, 6-DMATSSv_H287Y, and 6-DMATSMo (Y277H, H329Y, and double mutant
Y277H and H329Y). The corresponding proteins were produced and purified. The presence of 6DMATSx PTs (WT, and mutants) proteins were established via SDS-Page (Figure 18). The
molecular weight of the 6-DMATS Sa, 6-DMATS Sv and 6-DMATSMo enzymes were 39.91 kDa,
40.87 kDa, and 40.59 kDa, respectively. HPLC analysis of the His mutant of the 6-indole-PTs
utilizing the PriB_H312Y reaction condition, demonstrated His mutation to Tyr in these enzymes
seems to produce compounds other than C-6 normal prenylated compound (Figure 19). Table 2
summarized the histidine\ tyrosine mutagenesis on the active site of PriB, 6-DMATS Sa, 6-DMATS
Sv

and 6-DMATSMo, and their products.

Figure 18. SDS-PAGE analysis for purified 6-DMATSx PTs and their mutant’s proteins.
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Prenylated L-Trp
L-Trp

6-DMAT

Prenylated L-Trp
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L-Trp
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6-DMAT
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Figure 19. HPLC identification of the enzyme products of DMATS (sa, sv, mo) and their mutants. The enzymes (1
uM) were incubated (37°C in 16 hr) with 50 mM Tris/ HCl (pH 8.0), 1 mM DMAPP and 0.5mM of L-Trp using
Method A
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Table 2. Summary of histidine and tyrosine mutations on ArPTs

C-6 ArPT enzymes

PriB_H312 position PriB_Y364 position

Products

PriB (WT)

His312

Tyr364

1 product

6-DMATSSa (WT)

His284

Tyr336

1 product

6-DMATSSv (WT)

His287

Tyr339

1 product

6-DMATSMo (WT)

Tyr277

His329

More than 1 product

PriB_H312Y

Tyr312

Tyr364

~ 4 products

6-DMATSSa_H284Y

Tyr284

Tyr336

~ 4 products

6-DMATSSv_H287Y

Tyr287

Tyr339

~ 4 products

6-DMATSMo_Y277H

His277

His329

1 product

6-DMATSMo_H329Y

Tyr277

Tyr329

~ 4 products

6-DMATSMo_dm

His277

Tyr329

1 product

Structural analysis and site-directed mutagenesis have assisted in understanding the role of some
residues within the PT active site as well as changing the regiospecificity or substrate selectivity.
A previous study in FgaPT2 showed the role of acid-base residues during prenylation (Glu89 and
Lys174) (Figure 21). FgaPT2_Glu89 probably have a significant role in enhancing the
electrophilic substitution reaction of the L-Trp indole nucleus by forming a hydrogen bond between
the indole N-H and the carboxylate group of Glu89. Mutation of Glu89 to alanine has completely
abolished the activity, which shows the importance of this residue in the reaction mechanism
(Metzger et al., 2009). FgaPT2_Glu89 corresponds to PriB_Glu94 (Figure 21). The Glu89 in
FgaPT2 also corresponds to other PTs such as Glu116 in CdpNPT, Glu102 in FtmPT1, Glu89 in
TleC and Glu106 in MpnD (Metzger et al., 2009). This shows the importance of Glu residue at
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this position in most PTs. FgaPT2_Lys174 is placed conveniently in the catalytic binding pocket
to catalyze prenylation during the formation of the final prenylated product. Furthermore, the
indole ring of L-Trp substrate and the aromatic ring of Tyr345 in FgaPT2 sandwich the prenyl
moiety of DMAPP. These interactions maintain the carbocation intermediate via cation–
π interactions which expedite the first ionization stride (Tanner, 2015). Substitution of Lys174 to
other residue diminished the activity of the biocatalysts. Interestingly, mutation of Lys174 to
alanine has produced a new compound by changing the prenylation from normal C-4 to reverse C3 (Luk et al., 2011).

In this study, we have analyzed the PriB PTs active site. Among all the key residues that surround
the substrate, we have chosen the potential residue that could control the regiospecificity, which
we proposed to be His312. Noticeably, histidine residue is conserved in other C-6 prenylation PTs,
for instance, 6-DMATSSa and 6-DMATSSv. Also, the proximity of the basic residue His312 to C6 of the indole ring in the L-Trp substrate, and the role of the basic residue histidine that seems to
play a major role in the mechanism of reaction in ArPTs enzymes make it the first candidate for
mutagenesis. Figure 20 demonstrates a proposed mechanism of the PriB enzymatic reaction based
on the previous study on FgaPT2 enzyme. We propose that Glu94 will form a hydrogen bond with
the nearby nitrogen atom of the Trp indole ring. Moreover, we propose that His312 plays a role as
a general base by abstracting the proton from the indole ring during catalysis (Figure 21) as the
case with FgaPT2_Lys174. It is worth to mention that histidine and tyrosine residues have shown
significant roles in the catalysis mechanism in other enzymes (non-PT). For example, two histidine
residues (His47, His12) have shown essential role in the acid-base reaction mechanism of
sphingomyelinases D (spider venom) to hydrolyze sphingomyelin (Murakami et al., 2006). In
addition, the tyrosine (Tyr166) residue also showed an important role in E. coli 2,4-dienoyl-CoA
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reductase enzyme. The Tyr166 donate a proton to the C4 atom during substrate reduction.
Remarkably, replacement of Tyr166 to phenylalanine generated a new compound 3-decenoyl-CoA
instead of 2,4-dienoyl-CoA (Tu et al., 2008). These studies show the significance of His and Tyr
residues in abstracting and donating hydrogens in catalysis.
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Figure 20. Theoretical enzymatic catalysis of DMATS in PriB

A

B

Figure 21. A (PriB), and B (FgaPT2) shows that both E94 (PriB) and E89 (FgaPT2) carboxylate group bind to
indole N-H via hydrogen bond (2.7 Å for both enzymes), also the nearest amino acid residues H312 and K174 to
the prenylation position C-6 (3.7 Å) for PriB and C-4 (3.2 Å) for FgaPT2

Figure 22 shows the structure alignment of PriB wt and PriB_H312Y. There are different
possibilities that could explain the loss of regiospecificity in PriB_H312Y such as [1] PriB_His312
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play a role in the catalytic reaction as proposed in Figure 20, is strategically distant from C-6 only
on the indole ring and not other sites. Mutation of His to the larger aromatic ring in Tyr would
extend to other C position such as C-5 and C-7. [2] the phenyl ring of Tyr (6- membered ring)
differ than His imidazole ring (5- membered ring), therefore the π−π interactions of the Tyr
residue could shift the substrate positions allow to produce different isomers. [3] His has been
shown to abstract and donate protons during catalysis while Tyr role donates a proton. This
suggests that a different mechanism might have occurred to produce the other derivatives. [4]
His312 could be participating in attacking the DMAPP (donor) and stabilizing normal prenylation,
whereas Tyr could stabilize normal/reverse or only reverse prenylation.

The rationale behind the fact that the activity of His312 mutants such as Gly, Glu, and Gln did not
affect the catalytic activity is unclear, and it needs further study to understand the role of these
mutations in catalysis.

Figure 22. Structure analog of mutation of His312 to Tyr (gray stick) in the PriB active site
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Chapter 4
CONCLUSION
This study exhibited the importance of His312 in the catalytic mechanism of PriB PTs. Structurebased enzyme engineering on PriB His312 to Tyr successfully altered the prenylation preference
from C-6 normal to form other isomers. Also, His mutation on other C-6 indoles PTs 6-DMATSSa,
6-DMATSSv, and 6-DMATSMo demonstrated other than single prenylated compound. Indeed,
further work needed to finish this study, including purification and characterization of the newly
formed compounds. Future goals would be to examine the permissiveness of mutant PriB enzymes
for drug diversification purposes.
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